Perioperative dexamethasone in high-grade gliomas: the short-term benefits and long-term harms

Dexamethasone has been commonly given to patients with a presumed new GBM in relatively large doses (6-16 mg daily for 1-2 weeks) since the 1960s without any rigorous evidence. This treatment with dexamethasone before the diagnosis and adjuvant therapy makes GBM patients unique compared to other new...

Full description

Saved in:
Bibliographic Details
Published inFrontiers in oncology Vol. 13; p. 1335730
Main Author Mistry, Akshitkumar M
Format Journal Article
LanguageEnglish
Published Switzerland Frontiers Media S.A 2023
Subjects
dexamethasone
glioblastoma
glioma
immunosuppression
survival
dexamethasone
glioma
immunosuppression
glioblastoma
survival
Online AccessGet full text

Cover

More Information
Summary:Dexamethasone has been commonly given to patients with a presumed new GBM in relatively large doses (6-16 mg daily for 1-2 weeks) since the 1960s without any rigorous evidence. This treatment with dexamethasone before the diagnosis and adjuvant therapy makes GBM patients unique compared to other newly diagnosed cancer patients. While dexamethasone may be beneficial, recent studies suggest that this potent immunosuppressant with pleiotropic effects is harmful in the long term. This perspective article summarizes the disadvantages of perioperative dexamethasone from multiple facets. It concludes that these growing data mandate rigorously testing the benefits of using perioperative dexamethasone.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:2234-943X
2234-943X
DOI:10.3389/fonc.2023.1335730